Literature DB >> 15938133

alpha-keto acids accumulating in maple syrup urine disease stimulate lipid peroxidation and reduce antioxidant defences in cerebral cortex from young rats.

Raquel Bridi1, César A Braun, Giovanni K Zorzi, Clóvis M D Wannmacher, Moacir Wajner, Eduardo G Lissi, Carlos Severo Dutra-Filho.   

Abstract

Maple syrup urine disease (MSUD) is an inherited neurometabolic disorder caused by deficiency of branched-chain alpha-keto acid dehydrogenase complex activity which leads to tissue accumulation of the branched-chain alpha-keto acids (BCKAs) alpha-ketoisocaproic acid (KIC), alpha-ketoisovaleric acid (KIV) and alpha-keto-beta-methylvaleric acid (KMV) and their respective amino acids. Neuropathologic findings characteristic of the disease are cerebral edema and atrophy, whose pathophysiology is poorly known. In the present study, we investigated the in vitro effect of BCKAs on various parameters of oxidative stress, namely chemiluminescence (CL), thiobarbituric acid-reactive substances (TBA-RS), total radical-trapping antioxidant potential (TRAP), total antioxidant reactivity (TAR), and the activities of the antioxidant enzymes catalase (CAT), glutathione peroxidase (GPx), and superoxide dismutase (SOD) in cerebral cortex of 30-day-old rats. The major effects observed were with KIC, which significantly increased CL and TBA-RS measurements, decreased TRAP and TAR values, and markedly inhibited GPx activity. KMV and KIV increased CL and decreased TRAP and TAR values. In contrast, these compounds did not affect CAT and SOD activities. Taken together, it was shown that: the BCKAs studied stimulated lipid peroxidation and reduced the brain antioxidant defences, suggesting an increased production of free radicals. In case the in vitro effects here detected also occur in vivo in MSUD, it can be presumed that oxidative stress might contribute, at least in part, to the brain damage found in the affected patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15938133     DOI: 10.1007/s11011-005-4152-8

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  35 in total

1.  Visible chemiluminescence from rat brain homogenates undergoing autoxidation. II. Kinetics of the luminescence decay.

Authors:  E A Lissi; T Cáceres; L A Videla
Journal:  Free Radic Biol Med       Date:  1988       Impact factor: 7.376

Review 2.  Human complex I defects in neurodegenerative diseases.

Authors:  A H Schapira
Journal:  Biochim Biophys Acta       Date:  1998-05-06

3.  Maple syrup urine disease: interrelations between branched-chain amino-, oxo- and hydroxyacids; implications for treatment; associations with CNS dysmyelination.

Authors:  E Treacy; C L Clow; T R Reade; D Chitayat; O A Mamer; C R Scriver
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

4.  Inhibition of mitochondrial pyruvate transport by phenylpyruvate and alpha-ketoisocaproate.

Authors:  A P Halestrap; M D Brand; R M Denton
Journal:  Biochim Biophys Acta       Date:  1974-10-10

5.  Glutathione peroxidase.

Authors:  A Wendel
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

6.  Kinetics and mechanism of the chemiluminescence associated with the free radical-mediated oxidation of amino acids.

Authors:  A Aspée; E A Lissi
Journal:  Luminescence       Date:  2000 Sep-Oct       Impact factor: 2.464

7.  Elevation of amino acids in the interstitial space of the rat brain following infusion of large neutral amino and keto acids by microdialysis: alpha-ketoisocaproate infusion.

Authors:  H R Zielke; Y Huang; J T Tildon; C L Zielke; P J Baab
Journal:  Dev Neurosci       Date:  1996       Impact factor: 2.984

8.  Indomethacin reduces lipid peroxidation in rat brain homogenate by binding Fe2+.

Authors:  Shailendra Anoopkumar-Dukie; Barbara Lack; Kerry McPhail; Tebello Nyokong; Zaynab Lambat; Deepa Maharaj; Santy Daya
Journal:  Metab Brain Dis       Date:  2003-03       Impact factor: 3.584

9.  Hydroperoxide-initiated chemiluminescence: an assay for oxidative stress in biopsies of heart, liver, and muscle.

Authors:  B Gonzalez Flecha; S Llesuy; A Boveris
Journal:  Free Radic Biol Med       Date:  1991       Impact factor: 7.376

10.  Glutamate and gamma-aminobutyric acid neurotransmitter systems in the acute phase of maple syrup urine disease and citrullinemia encephalopathies in newborn calves.

Authors:  P R Dodd; S H Williams; A L Gundlach; P A Harper; P J Healy; J A Dennis; G A Johnston
Journal:  J Neurochem       Date:  1992-08       Impact factor: 5.372

View more
  31 in total

Review 1.  Oxidative stress in phenylketonuria: what is the evidence?

Authors:  Graziela S Ribas; Angela Sitta; Moacir Wajner; Carmen R Vargas
Journal:  Cell Mol Neurobiol       Date:  2011-04-23       Impact factor: 5.046

2.  Creatine and antioxidant treatment prevent the inhibition of creatine kinase activity and the morphological alterations of C6 glioma cells induced by the branched-chain alpha-keto acids accumulating in maple syrup urine disease.

Authors:  Cláudia Funchal; Patrícia Fernanda Schuck; André Quincozes Dos Santos; Maria Caroline Jacques-Silva; Carmem Gottfried; Regina Pessoa-Pureur; Moacir Wajner
Journal:  Cell Mol Neurobiol       Date:  2006-02       Impact factor: 5.046

3.  Investigation of inflammatory profile in MSUD patients: benefit of L-carnitine supplementation.

Authors:  Caroline Paula Mescka; Gilian Guerreiro; Bruna Donida; Desirèe Marchetti; Carlos Alberto Yasin Wayhs; Graziela Schimitt Ribas; Adriana Simon Coitinho; Moacir Wajner; Carlos Severo Dutra-Filho; Carmen Regla Vargas
Journal:  Metab Brain Dis       Date:  2015-05-24       Impact factor: 3.584

Review 4.  Branched-chain amino acids in metabolic signalling and insulin resistance.

Authors:  Christopher J Lynch; Sean H Adams
Journal:  Nat Rev Endocrinol       Date:  2014-10-07       Impact factor: 43.330

5.  Effect of leucine administration to female rats during pregnancy and lactation on oxidative stress and enzymes activities of phosphoryltransfer network in cerebral cortex and hippocampus of the offspring.

Authors:  Itiane Diehl de Franceschi; Elenara Rieger; Alessandra Pinto Vargas; Denise Bertin Rojas; Aline Guimarães Campos; Virginia Cielo Rech; Luciane Rosa Feksa; Clóvis Milton Duval Wannmacher
Journal:  Neurochem Res       Date:  2013-01-01       Impact factor: 3.996

6.  Serum Markers of Neurodegeneration in Maple Syrup Urine Disease.

Authors:  Giselli Scaini; Tássia Tonon; Carolina F Moura de Souza; Patricia F Schuk; Gustavo C Ferreira; Joao Seda Neto; Tatiana Amorin; Ida Vanessa D Schwartz; Emilio L Streck
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

Review 7.  Cytoskeleton as a potential target in the neuropathology of maple syrup urine disease: insight from animal studies.

Authors:  R Pessoa-Pureur; M Wajner
Journal:  J Inherit Metab Dis       Date:  2007-06-14       Impact factor: 4.982

8.  Profiling of oxidative stress in patients with inborn errors of metabolism.

Authors:  Peter J Mc Guire; Aditya Parikh; George A Diaz
Journal:  Mol Genet Metab       Date:  2009-06-14       Impact factor: 4.797

9.  Hepatocyte transplantation (HTx) corrects selected neurometabolic abnormalities in murine intermediate maple syrup urine disease (iMSUD).

Authors:  Kristen J Skvorak; Elizabeth J Hager; Erland Arning; Teodoro Bottiglieri; Harbhajan S Paul; Stephen C Strom; Gregg E Homanics; Qin Sun; Erwin E W Jansen; Cornelis Jakobs; William J Zinnanti; K Michael Gibson
Journal:  Biochim Biophys Acta       Date:  2009-08-19

10.  Oxidative stress in plasma from maple syrup urine disease patients during treatment.

Authors:  Alethéa G Barschak; Angela Sitta; Marion Deon; Amanda T Barden; Carlos S Dutra-Filho; Moacir Wajner; Carmen R Vargas
Journal:  Metab Brain Dis       Date:  2007-11-17       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.